Pyelonephritis medical therapy

Urinary Tract Infections Main Page
Pyelonephritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pyelonephritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocaridogram
X Ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pyelonephritis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pyelonephritis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pyelonephritis medical therapy
CDC on Pyelonephritis medical therapy
Pyelonephritis medical therapy in the news
Blogs on Pyelonephritis medical therapy
Directions to Hospitals Treating Pyelonephritis
Risk calculators and risk factors for Pyelonephritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]

Overview

All patients with pyelonephritis should be treated empirically with antimicrobial therapy. Mild pyelonephritis may be managed with oral antimicrobial therapy, and an initial intravenous dose may be administered depending on local resistance patterns. Patients with dehydration, nausea, vomiting, or signs of sepsis should be admitted and should receive parenteral therapy. Medical therapies for pyelonephritis include fluoroquinolones, TMP-SMX, β-lactams, and aminoglycosides.

Medical Therapy

The medical therapy for pyelonephritis has a few important aspects to be kept in mind:

• All patients with pyelonephritis should be treated empirically with antimicrobial therapy.
• Before initiating antimicrobial treatment for suspected pyelonephritis, a urine culture and susceptibility test should always be performed.
• Mild pyelonephritis may be managed with oral antimicrobial therapy, and an initial intravenous dose may be administered depending on local resistance patterns. Patients with dehydration, nausea, vomiting, or signs of sepsis should be admitted and should receive parenteral therapy.
• Optimal management depends on the severity of illness at presentation, regional resistance data, and host factors.
• When local resistance patterns are unknown, an initial intravenous (IV) dose of a long-acting, broad-spectrum antimicrobial agent may be considered.
• Oral beta-lactams are less effective than either trimethoprim-sulfamethoxazole, fluoroquinolones, or aminoglycosides in eradicating uropathogens.
• Uncomplicated pyelonephritis due to MRSA is uncommon, and there is insufficient evidence to support empiric use of an MRSA-active agent.
• Pregnant women, patients who failed to respond to oral therapy, and patients with nausea, vomiting, high fever, marked leukocytosis, or dehydration should be hospitalized and managed with parenteral antibiotics.

Antimicrobial Therapy

As a broader rule, antibiotics are started only after the sample has been drawn for culture. Uncomplicated pyelonephritis is treated with specific and short duration (5 to 14 days) of antibiotics while complicated pyelonephritis is treated with broad spectrum and longer duration (at least 14-21 days) of antibiotics.In hospitalised cases treat IV until 24-48 patient afebrile, then start 2 weeks course of PO regimen for uncomplicated pyelonephritis.

• Pyelonephritis empiric therapy

• Outpatient treatment

• Preferred regimen, regional fluoroquinolone resistance < 10%: Ciprofloxacin 500 mg PO q12h x 7 days ± 400 mg IV in a single dose OR Ciprofloxacin XR 1000 mg PO q24h for 7 days OR Levofloxacin 750 mg PO q24h for 5 days OR Ofloxacin 400 mg Po bid ORMoxifloxacin 400 mg PO q24h
• Preferred regimen, regional fluoroquinolone resistance ≥ 10%: (Ciprofloxacin 500 mg PO q12h x 7 days ± 400 mg IV in a single dose OR Ciprofloxacin XR 1000 mg PO q24h for 7 days OR Levofloxacin 750 mg PO q24h for 5 days) AND (Ceftriaxone 1 g IV x 1 dose OR Gentamicin 7 mg/kg IV x 1 dose OR Tobramycin 7 mg/kg IV x 1 dose OR Amikacin 20 mg/kg IV x 1 dose)
• Alternative regimen (1): regional fluoroquinolone resistance < 10%: TMP-SMX 160/800 mg PO q12h x 14 days OR Amoxicillin-clavulanate 875/125 mg po q12h or 500/125 mg po tid or 1000 /125 mg po bid OR Cefdinir 300 mg po q12h or 600 mg po q24 OR Cefaclor 250-500 mg po q8h OR Cefpodoxime-proxetil 100-200 mg po q12h OR Cephalexin250-500 mg po q6h not studied well but effective.
• Alternative regimen (2): regional fluoroquinolone resistance ≥ 10%: TMP-SMX 160/800 mg PO q12h x 14 days AND (Ceftriaxone 1 g IV x 1 dose OR Gentamicin 7 mg/kg IV x 1 dose OR Tobramycin 7 mg/kg IV x 1 OR Amikacin 20 mg/kg IV x 1 dose
• Alternative regimen (3): (Amoxicillin–Clavulanate 500/125 mg PO q12h x 14 days OR Amoxicillin–Clavulanate 250/125 mg PO q8h x 5–7 days OR Cefaclor 500 mg PO q8h x 7 days) AND (Ceftriaxone 1 g IV in a single dose OR Gentamicin 7 mg/kg IV in a single dose OR Tobramycin 7 mg/kg IV in a single dose OR Amikacin 20 mg/kg IV in a single dose )
• Alternative regimen (4): TMP-SMX, 160mg and 800mg, twice daily for 3 days
• Alternative regimen (5): Fosfomycin, a single dose of 3g

• Inpatient treatment

• Preferred regimen (1): Ciprofloxacin 400 mg IV q12h for 10-14 days OR Levofloxacin 750 mg IV q24h for 10-14 days OR Gatifloxacin 400 mg IV q24h
• Preferred regimen (2): Ampicillin+gentamicin 150–200 mg/kg IV/day-MDD: 2 mg per kg load, then 1.7 mg per kg q8h or OD: 5.1 (7 if critically ill) mg/kg q24h
• Preferred regimen (3): Ceftriaxone 1-2 gm IV q24h
• Preferred regimen (4): Piperacillin-tazobactam 3.375 gm IV q4-6h
• Alternative regimen (1): Gentamicin 7 mg/kg IV q24h for 10-14 days ± Ampicillin 500 mg IV q6h for 10-14 days
• Alternative regimen (2): Tobramycin 7 mg/kg IV q24h for 10-14 days ± Ampicillin 500 mg IV q6h for 10-14 days
• Alternative regimen (3): Amikacin 20 mg/kg IV q24h for 10-14 days ± Ampicillin 500 mg IV q6h for 10-14 days
• Alternative regimen (4): Cefotaxime 1-2 g IV q8h for 10-14 days ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
• Alternative regimen (5): Ceftriaxone 1 g IV q24h ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
• Alternative regimen (6): Ceftazidime 12 g IV q8h ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
• Alternative regimen (7): Ampicillin-Sulbactam 1.5 g IV q6h ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
• Alternative regimen (8): Piperacillin-Tazobactam 3.375 g IV q4-6h ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
• Alternative regimen (9): Ticarcillin-Clavulanate 3.1 g IV q4-6h ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
• Alternative regimen (10): Meropenem 500 mg IV q8h for 10-14 days
• Alternative regimen (11): Ertapenem 1 g IV q24h for 10-14 days
• Alternative regimen (12): Doripenem 500 mg IV q8h for 10-14 days
• Alternative regimen (13): Aztreonam 1 g IV q8-12h for 10-14 days

• Pathogen-directed therapy

• Gram positive cocci

Treat with ampicillin-sulbactam with or without an aminoglycoside if a gram positive cocci is the casitive organism.

• Enterococcus spp.

• Preferred regimen: Ampicillin 2 g IV q6h for 10-14 days AND Gentamicin 3-5 mg/kg/day IV q8h for 10-14 days

• Specific considerations

• Pregnancy

In event of a pregnancy the treatment of pyelonephritis ha stop be done in an in patient setting due to higher and severe complications risks. Intravenous antibiotics should be given for the initial 1-2 days at least until the patient is not febrile and then continued on oral therapy for 10-14 days.

• Pyelonephritis empiric therapy

• Preferred regimen (1): Ceftriaxone 1-2 g IM q24h or IV cefazolin for 24-48hrs followed by oral cephalexin therapy for 10-14 days
• Preferred regimen (2): Aztreonam 1 g IV q8-12h for 10-14 days
• Preferred regimen (3): Piperacillin-Tazobactam 3.375-4.5 g IV q6h for 10-14 days
• Preferred regimen (4): Meropenem or Ertapenem or Doripenem 500 mg IV q6h for 10-14 days
• Note: Fluoroquinolones and aminoglycosides should be avoided in pregnant patients

• Followup Urinalysis

• Pregnant women are followed up with urinalysis and urine cultures every month to rule out bacteriuria which can trigger another episode of pyelonephritis.